Structural analyses to identify selective inhibitors of glyceraldehyde 3-phosphate dehydrogenase-S, a sperm-specific glycolytic enzyme by Danshina, Polina V. et al.
ORIGINAL RESEARCH
Structural analyses to identify
selective inhibitors of glyceraldehyde
3-phosphate dehydrogenase-S,
a sperm-specific glycolytic enzyme
PolinaV.Danshina1,WeidongQu1,5, BrendaR.Temple2,Rafael J. Rojas3,6,
Michael J. Miley4, Mischa Machius4,7, Laurie Betts1, and
Deborah A. O’Brien1,*
1Department ofCell Biology andPhysiology,UniversityofNorthCarolina School ofMedicine,ChapelHill,NC27599,USA 2R.L. Juliano Structural
Bioinformatics Core Facility, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA 3Department of Pharmacology,
UniversityofNorthCarolina SchoolofMedicine,ChapelHill,NC27599,USA4MacromolecularX-RayCrystallographyCoreFacility,Universityof
North Carolina School of Medicine, Chapel Hill, NC 27599, USA
5Present address: Key Laboratory of Public Health Safety, Ministry of Education, Department of Environmental Health, School of Public Health,
Fudan University, Shanghai 200032, China
6Present address: Dart NeuroScience, LLC, San Diego, CA 92131, USA
7Present address: 230 Jamestown Road, Pittsboro, NC 27312, USA
*Correspondence address. E-mail: dao@med.unc.edu
Submitted on January 15, 2016; resubmitted on February 11, 2016; accepted on February 22, 2016
study hypothesis: Detailed structural comparisons of sperm-specific glyceraldehyde 3-phosphate dehydrogenase, spermatogenic
(GAPDHS) and the somatic glyceraldehyde 3-phosphate dehydrogenase (GAPDH) isozyme should facilitate the identification of selective
GAPDHS inhibitors for contraceptive development.
studyfinding: This study identified a small-moleculeGAPDHS inhibitor withmicromolar potency and.10-fold selectivity that exerts the
expected inhibitory effects on sperm glycolysis and motility.
what is known already: Glycolytic ATP production is required for sperm motility and male fertility in many mammalian species.
Selective inhibition of GAPDHS, one of the glycolytic isozymes with restricted expression during spermatogenesis, is a potential strategy for
the development of a non-hormonal contraceptive that directly blocks sperm function.
study design, samples/materials, methods: Homologymodeling and x-ray crystallographywere used to identify structural
features that are conserved inGAPDHSorthologs inmouse andhuman sperm, but distinct fromtheGAPDHorthologs present in somatic tissues.
We identified three binding pockets surrounding the substrate and cofactor in these isozymes and conducted a virtual screen to identify small-
molecule compounds predicted to bind more tightly to GAPDHS than to GAPDH. Following the production of recombinant human andmouse
GAPDHS, candidate compounds were tested in dose–response enzyme assays to identify inhibitors that blocked the activity of GAPDHSmore
effectively than GAPDH. The effects of a selective inhibitor on the motility of mouse and human sperm were monitored by computer-assisted
sperm analysis, and sperm lactate production was measured to assess inhibition of glycolysis in the target cell.
main results and the role of chance: Our studies produced the first apoenzyme crystal structures for human and mouse
GAPDHS and a 1.73 A˚ crystal structure for NAD+-bound human GAPDHS, facilitating the identification of unique structural features of this
sperm isozyme. In dose–response assays T0501_7749 inhibited human GAPDHS with an IC50 of 1.2 mM compared with an IC50 of 38.5 mM for
the somatic isozyme. This compound caused significant reductions in mouse sperm lactate production (P ¼ 0.017 for 100 mM T0501_7749
versus control) and in the percentage of motile mouse and human sperm (P values from,0.05 to,0.0001, depending on incubation conditions).
limitations, reasons for caution: The chemical properties of T0501_7749, including limited solubility and nonspecific protein
binding, are not optimal for drug development.
wider implications of thefindings: This study provides proof-of-principle evidence thatGAPDHS can be selectively inhibited,
causing significant reductions in sperm glycolysis andmotility. These results highlight the utility of structure-based drug design and support further
exploration of GAPDHS, and perhaps other sperm-specific isozymes in the glycolytic pathway, as contraceptive targets.
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Introduction
Extensive tissue-specific gene expression is a hallmark of spermatogen-
esis, providing a large number of sperm-specific proteins that are poten-
tial targets formale contraception (Schultz et al., 2003;Matzuk andLamb,
2008). The central metabolic pathway of glycolysis presents an extraor-
dinary example of tissue specificitywithin themale germ line.Mammalian
sperm have distinct isozymes at most steps of this pathway, resulting
from germ cell-specific expression of at least three genes and from
novel alternative splicing events (Eddy et al., 2003; Vemuganti et al.,
2007; Ijiri et al., 2013). Enzymes are typically considered good candidates
for pharmaceutical intervention and account for.25% of themolecular
targets for all known drugs (Nass and Strauss, 2004).
Glyceraldehyde3-phosphatedehydrogenase, spermatogenic (GAPDHS),
in particular, is a promising contraceptive target. This sperm-specific
glycolytic isozyme is expressed only in the post-meiotic period of sper-
matogenesis, replacing the somatic isozyme (GAPDH) in mammalian
sperm (Welch et al., 1992, 2000; Bunch et al., 1998). Inmultiplemamma-
lian species the sperm isozyme shares 70% amino acid identity
with the somatic isozyme and has a novel proline-rich extension at
the N-terminus. This N-terminal extension plays a role in anchoring
GAPDHS to the fibrous sheath in the principal piece of the sperm flagel-
lum (Bunch et al., 1998; Krisfalusi et al., 2006), but is not required for
enzymatic activity (Elkina et al., 2010; Sexton et al., 2011).Gene targeting
studies in mice established that GAPDHS (Miki et al., 2004) and other
sperm-specific isozymes in the glycolytic pathway (Odet et al., 2008;
Danshina et al., 2010; Nakamura et al., 2013) are essential for sperm
motility and male fertility. These studies demonstrate the importance
of glycolysis for sperm energy production. Spermatogenesis and sperm
production appear normal in mice lacking GAPDHS, providing evidence
that inhibition of this isozyme should not impair testicular function
(Miki et al., 2004).
Like the somatic isozyme, homotetrameric GAPDHS catalyzes the
oxidation and phosphorylation of glyceraldehyde 3-phosphate (GAP)
to form1,3-bisphosphoglycerate, a reaction that requiresNAD+ and in-
organic phosphate. This reaction occurs at an important transition point
in glycolysis between the enzymatic steps that consume and generate
ATP. Consequently, ATP levels in mouse sperm lacking GAPDHS are
10% of wild-type levels immediately after collection in glucose-
containing M16 medium, which fuels the ATP-consuming steps of gly-
colysis (Miki et al., 2004). The requirement for glycolytic ATP production
has also been demonstrated for human sperm (Williams and Ford, 2001;
Nascimento et al., 2008) and sperm from several other mammalian
species (Storey, 2008; Mukai and Travis, 2012).
As a contraceptive target,GAPDHSmustbe subject to selective inhib-
ition that does not disrupt glycolysis in other tissues. Initial evidence for
selective inhibition was provided by early studies of a-chlorohydrin
(3-chloro-1,2-propanediol) conducted before GAPDHS was identified
as a distinct sperm-specific isozyme (reviewed in Jones, 1978; Jones
and Cooper, 1999). S-3-chlorolactaldehyde, the major metabolite of
a-chlorohydrin and related compounds, inhibited GAPDHS, sperm gly-
colysis andmotility in a dose-dependentmanner. These effects on sperm
occurred at concentrations that did not inhibit GAPDH activity in other
tissues (Brown-Woodman and White, 1975; Brown-Woodman et al.,
1978; Ford and Harrison, 1983). Efforts to develop these agents as
contraceptives were abandoned due to toxic effects at high doses,
although impurities and racemic mixtures of reactive compounds may
have contributed to the observed toxicity (Jones and Cooper, 1999).
To assess the potential for selective inhibition of GAPDHS, we used
structural analyses to highlight differences between the sperm and
somatic isozymes that are conserved between species.We initially con-
structed homologymodels of human andmouseGAPDHS andGAPDH
templated on the 2.0 A˚ crystal structure of Palinurus versicolor GAPDH
(PDB 1CRW; Shen et al., 2000). Active site structural features of our
models were later confirmed in high resolution crystal structures of
human GAPDHS (PDB 3H9E, Chaikuad et al., 2011; PDB 5C7L and
PDB 5C7O, this study), mouse GAPDHS (PDB 5C7I, this study) and
human GAPDH (PDB 1U8F, Jenkins and Tanner, 2006).We conducted
virtual screening to identify small-molecule compounds that are pre-
dicted to bind more tightly to GAPDHS than GAPDH. These com-
pounds were then tested in enzymatic assays to compare inhibition of
the sperm and somatic enzymes, and in functional assays to determine
their effects on sperm metabolism and motility.
Materials andMethods
Reagents
Standard reagents were purchased from Sigma-Aldrich (St. Louis, MO,USA)
with the exception of glucose, magnesium sulfate heptahydrate, sodium
bicarbonate, sodium chloride, sodium isopropyl-b-D-thiogalactopyranoside
(IPTG), sodium pyruvate, tris(2-carboxyethyl)phosphine (TCEP) (Thermo-
Fisher Scientific, Waltham, MA, USA); potassium chloride, potassium phos-
phate (Mallinckrodt Baker, Phillipsburg, NJ, USA); penicillin/streptomycin
100X stock solution containing 10 000 U/ml of penicillin G and 10 mg/ml
of streptomycin (Gemini Bio-Products,West Sacramento, CA, USA); cOm-
plete protease inhibitor cocktail (Roche Life Science, Indianapolis, IN, USA);
and PEG 3350 (Emerald Biosystems, Bainbridge Island, WA, USA).
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Homology modeling and virtual screening
The 2.0 A˚ crystal structure of Palinurus versicolorGAPDH (PDB 1CRW; Shen
et al., 2000) was used as a template for homology modeling of human and
mouse GAPDH and GAPDHS isozymes, and binding sites for GAP and
NAD+ were determined by reference to structures PDB 1DC4 and 1DC6
(Yun et al., 2000). The proline-rich N-terminal extensions that are specific
to the sperm isozymes were not included in these models. Therefore,
mouse GAPDHS was modeled without the first 105 amino acids of its
sequence, and human GAPDHSwithout the first 75 amino acids. Homology
models were constructed using themodeler module of the Insight II molecu-
lar modeling program (Accelrys, San Diego, CA, USA). Final structures were
tested for sequence-structure compatibility using the Verify function in the
Profiles-3D module. Results were displayed graphically using the PyMOL
Molecular Graphics System (Schro¨dinger, LLC, New York, NY, USA).
To assess the potential for selective inhibition of the sperm isozymes, we
conducted virtual screening with the SYBYL 6.9 molecular modeling
program (Tripos, St. Louis,MO,USA). The SiteIDmodulewas used to identify
three solvent-accessible binding pockets surrounding the active site in our
homologymodels. After pre-filtering by size, compounds from theMaybridge
small molecule database were docked into each of the binding pockets using
the SYBYL FlexX algorithm for the flexible docking of small ligands (Rarey
et al., 1995). Protein-ligand interaction scores were computed for each
isozyme, and the predicted discrimination between sperm and somatic iso-
zymes was calculated as the difference between interaction scores. Docking
was repeated thirty times for the compounds with the largest discrimination
scores for the human isozymes to confirm that these compounds consistently
docked in the predicted binding pocket.
Expression and purification of recombinant
proteins
As in previous studies (Frayne et al., 2009; Elkina et al., 2010; Sexton et al.,
2011), we expressed only trace amounts of full-length mouse or human
GAPDHSeven thoughwepurchasedDNA sequenceswith codon usage opti-
mized for expression in Escherichia coli (GeneArt, Regensburg, Germany).
Therefore, we subcloned the optimized sequences and expressed truncated
forms of the sperm isozymes lacking their proline-rich N-terminal extensions
(tGAPDHS). Several fusion constructs were tested to optimize expression
of the sperm isozymes.
The DNA fragment encoding human tGAPDHS (amino acids 76–408)
was cloned into the pGEX-4T-1 vector (GEHealthcare Life Sciences, Piscat-
away, NJ, USA) for expression as a glutathione S-transferase (GST) fusion
protein. Recombinant protein was expressed in gapA-deficient E. coli
DS112, strain K-12 (Yale Coli Genetic Stock Center, New Haven, CT,
USA) to avoid the formation of mixed tetramers that contain bacterial
GAPDH (Frayne et al., 2009; Sexton et al., 2011). Cells were grown at
378C in M9 minimal media supplemented with 1% glycerol, 0.1% casamino
acids, 0.4% sodium succinate, 0.001% thiamine, 0.004% methionine,
0.004% tryptophan and 0.002% uracil until absorbance at 600 nm was
0.5–0.6. Expression was induced by 0.1 mM IPTG during overnight culture
at 188C. Cells were harvested by centrifugation and resuspended in
phosphate-buffered saline (PBS: 136 mM NaCl, 2.7 mM KCl, 10 mM
NaH2PO4.7H2O, 1.7 mM KH2PO4; pH 7.4) supplemented with 2 mM
dithiothreitol (DTT), 5 mg/ml lysozyme, 5 mg/ml DNase I and cOmplete
protease inhibitor cocktail. After incubation for 30 minon ice, the suspension
wassonicatedwith shortpulses for2 minand centrifugedat30 000g for 1 hat
48C. The resulting supernatant was loaded onto a glutathione Sepharose 4B
(GE Healthcare Life Sciences) column prepared according to the manufac-
turer’s instructions and washed with PBS containing 2 mM DTT. To
remove the GST tag, the column was incubated overnight at room tempera-
turewith40 units of bovine thrombin/ml bed volume. Cleaved tGAPDHS
was eluted, frozen in liquid nitrogen and stored at 2708C.
The DNA fragment encoding mouse tGAPDHS (amino acids 106–438)
was subcloned into the pMal vector (New England Biolabs, Ipswich, MA,
USA), which incorporates a thrombin-cleavable maltose-binding protein
(MBP) tag. Recombinant mouse tGAPDHS was expressed using the same
procedure described for human tGAPDHS, except that buffer A (20 mM
Tris–HCl, 200 mM NaCl, 10 mM EDTA, pH 7.4) replaced PBS in the cell
lysis solution. The clarified supernatant was loaded onto an amylose
column (NewEnglandBiolabs) equilibratedwithbufferAand5%glycerol, fol-
lowedbyovernight incubation at roomtemperaturewith40unitsof bovine
thrombin/ml bed volume. The eluate from this column, containing recom-
binant protein and a fraction of the cleaved MBP tag, was dialyzed against
2000volumesof 20 mMTris–HCl, 25 mMNaCl, 2 mMb-mercaptoethanol,
pH 8.0. Following dialysis, the protein solution was loaded onto a diethylami-
noethyl (DEAE)-Sepharose column equilibrated with 20 mM Tris–HCl,
10 mM NaCl, 2 mM DTT, pH 8.0, which retained the MBP tag. Mouse
tGAPDHS was eluted, frozen in liquid nitrogen and stored at 2708C.
Mouse somatic GAPDHwas expressed as a GST-fusion protein and puri-
fied according to the sameproceduresused for human tGAPDHS.Thepurity
of all recombinant enzyme preparations was confirmed by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (Sexton et al., 2011). Human
somatic GAPDH, purified from erythrocytes, was purchased from Sigma-
Aldrich (Cat. No. G6019).
Crystallization of tGAPDHS
Crystal structures were obtained using resources in the Macromolecular
X-Ray Crystallography Core Facility at the University of North Carolina
School of Medicine (Chapel Hill, NC,USA) as well as the SER-CAT beamline
at the Advanced Photon Source of the Argonne National Laboratory
(Lemont, IL, USA). The PACT Suite screening kit (Qiagen, Valencia, CA,
USA) was used to assess multiple conditions for crystallization with the
hanging-drop vapor-diffusion method. Apoenzyme crystals of mouse
tGAPDHS were obtained when purified protein (3 mg/ml in PBS) was
mixed in a 1:1 volume ratio with a reservoir solution containing 0.2 M potas-
sium thiocyanate, 0.1 M Bis-Tris propane, pH 6.5, 20% PEG 3350. These
crystals, which appeared in the hanging drop after 6 days at 208C,were cryo-
protected with 25% glycerol in crystal growth solution and then flash-frozen
in liquid nitrogen.
Human tGAPDHS was concentrated to 10 mg/ml in 10 mM HEPES
(pH 7.5), 500 mM NaCl, 5% glycerol, 0.5 mM TCEP, 0.01% of sodium
azide and stored at 2808C. Purified protein was mixed in a 1:1 volume
ratio with each of the selected crystallization conditions from the screening
kit. Crystals appeared within two days at 208C. Apoenzyme crystals were
obtained with F8 PACT Suite reservoir conditions (0.2 M Na2SO4, 0.1 M
Bis Tris propane, pH 6.5, 20% PEG 3350) and holoenzyme crystals of
tGAPDHS complexed with NAD+ were obtained with E5 PACT Suite res-
ervoir conditions (0.2NaNO3, 20%PEG3350).Crystalswere cryoprotected
and flash-frozen as described for mouse tGAPDHS.
Diffraction data were collected from flash-frozen crystals at 100 K either
on a Rigaku rotating anode generator using the Saturn944 CCD detector
(mouse apoenzyme), or the Advanced Photon Source SER-CAT beamline
(human apo- andholoenzymes).Crystal structureswere solvedbymolecular
replacement with PHASER (McCoy et al., 2007) in the CCP4 program suite
(Winn et al., 2011), using human placenta GAPDH (PDB 1U8F, Jenkins and
Tanner, 2006) and human sperm GAPDHS (PDB 3H9E, Chaikuad et al.,
2011) structures as search models for the mouse and human sperm
enzymes, respectively. The 2.01 A˚ mouse tGAPDHS apoenzyme structure
was refined initially usingCCP4RefMac5 (Vagin et al., 2004), with final refine-
ments using PHENIX (Adams et al., 2010) and keeping the Rfree constant.
Human tGAPDHS structures were refined to 1.86 A˚ (apoenzyme) and
1.73 A˚ (holoenzyme) using PHENIX (Adams et al., 2010). Data collection
and refinement statistics are shown in Table I.
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Enzyme inhibition and kinetics
ThedehydrogenaseactivityofGAPDHorGAPDHSwasmonitored inakinetic
assay that measures NADH accumulation at 340 nm (Schmalhausen et al.,
1997). The assay was adapted for 96-well plates and the final reaction
mixture in each well (200 ml) contained 100 mM glycine, 100 mM potassium
phosphate, 5 mM EDTA, 0.5 mM NAD+, 0.5 mM D-glyceraldehyde-
3-phosphate (Sigma-Aldrich, 39705) and 0.5 mg of protein (GAPDH or
tGAPDHS). One enzyme unit is defined as the amount of enzyme necessary
for the formation of 1 mmole 1,3-diphosphoglycerate/min. Twenty-five com-
pounds identified as potential selective inhibitors of GAPDHS in our virtual
screen were purchased (Ryan Scientific, Mount Pleasant, SC, USA) and
tested for inhibition of both sperm and somatic isozymes. Stock solutions
(10 mM)of each compoundwere prepared in dimethyl sulfoxide (DMSO), ali-
quoted and frozen at2208C. Following pre-incubationof the test compounds
withenzymeandNAD+ for30 minat378C,enzymatic reactionswere initiated
by the addition of GAP. Triplicate samples were included for each concentra-
tion tested and DMSO controls were included in each assay. IC50 values for
each compound were calculated in Prism (GraphPad Software, La Jolla, CA,
USA) using the four parameter nonlinear regression model. Results are
expressed as the mean+ SEM for at least three different experiments with
different batches of recombinant isozymes.
.............................................................................................................................................................................................
Table I Data collection and refinement statistics for human and mouse truncated glyceraldehyde 3-phosphate
dehydrogenase, spermatogenic (tGAPDHS) structures.
Parameter Human tGAPDHS-NAD1 Human tGAPDHS-apo Mouse tGAPDHS-apo
PDB code 5C7O 5C7L 5C7I
Data collection






Wavelength (A˚) 1.0746 1.0746 1.5418
Space group C2 P 3121 P 3121
Monomers/asymmetric unit 2 2 2
Unit cell dimensions a ¼ 144.4, b ¼ 71.8, c ¼ 80.8;
a ¼ g ¼ 90.08, b ¼ 123.018
a ¼ 86.9, b ¼ 86.9, c ¼ 159.1;
a ¼ b¼90.08, g ¼ 120.08
a ¼ 86.7, b ¼ 86.7, c ¼ 158.4;
a ¼ b ¼ 90.08, g ¼ 120.08
Resolution range (A˚) 31.71–1.73 (1.79–1.73) 38.2–1.86 (1.93–1.86) 30.6–2.01 (2.08–2.01)
# of unique reflections 72 313 (1819) 59 104 (1462) 44 704 (4260)
Completeness 93.9 (55.7) 99.8 (99.9) 95.9 (92.9)
I/sI 19.2 (2.0) 17.5 (2.1) 23.7 (4.6)
Rmeas 0.091 0.169 0.071
Rpim 0.044 0.052 Not calculated
CC1/2 0.922 0.895 Not calculated
CC* 0.981 0.952 Not calculated
Redundancy 4.2 (4.0) 8.7 (6.3) 3.5 (3.1)
Refinement
# of non-hydrogen atoms (protein/ligand/water O) 5218/98/629 5210/384 5107/447
Number of reflections and cutoff 68 115/F . 0sF 54 421/F . 0sF 44 704/F. 0sF
Rwork (%) 13.7 (18.9) 18.7 (22.1) 19.2 (23.2)
Rfree (%) 16.6 (21.2) 22.7 (26.0) 21.3 (27.8)
Average B-factor (A˚2) (protein/ligand/water O) 23.8/26.5/35.2 29.5/NA/33.9 29.2/NA/35.7
Wilson B-factor 19.7 23.1 24.6
RMSD bond length (A˚) 0.005 0.013 0.004
RMSD bond angles (o) 1.03 1.4 0.907
Ramachandran favored/allowed (%) 95.9/3.8 96.3/3.4 95.2/4.5
Ramachandran outliers (%) 0.3 0.3 0.3
Values in parentheses are for highest resolution shells.
Standard crystallography statistics are shown for three structures determined for tGAPDHS. X-ray diffraction provides the intensity (I ) of n measurements of reflections, which yield
structure factor (F ) valueswith defined indices (h, k, l ).R factor statisticsmeasure agreement between the experimentalX-ray diffraction data and the crystallographicmodel.Rmeas andRpim
are indicators of data quality and Rwork and Rfree assess the quality of the model. RMSD refers to root-mean-square deviation. Formulas for calculating the statistics shown are:


















i¼1,nIi(hkl)), where ,I. ¼ average I of the nmeasurements.
Rwork¼ (
∑
hkl |Fobs(hkl) 2 Fcalc(hkl)|/
∑
hkl Fobs(hkl)), ALL reflections, obs ¼ observed, calc ¼ calculated.
Rfree¼ (
∑
hkl |Fobs(hkl) 2 Fcalc(hkl)|/
∑
hkl Fobs(hkl)), 5% randomly chosen reflections NOT included in refinement.
CC1/2 ¼ Pearson’s correlation coefficient between randomly chosen ‘half’ of each data set.
CC* ¼ (2 CC1/2/1+ CC1/2) 12.
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Kinetic assays of inhibition were conducted for each substrate (GAP or
NAD+) at several inhibitor concentrations (1–100 mM) and the results
were analyzed with Enzyme Kinetics Pro (ChemSW, Fairfield, CA, USA).
Duplicate samples were measured in all assays, which were repeated
three times with different enzyme preparations. Data were fit using the
Lineweaver–Burk linearization method to identify the mode of inhibition
and estimates Ki values.
Inhibitor effects on spermmotility
and metabolism
Mouse sperm were collected from the cauda epididymides of adult CD1
males (.8 weeks old; Charles River Laboratories, Raleigh, NC, USA) in
human tubal fluid (HTF) medium as described previously (Goodson et al.,
2011). All procedures involving mice were performed according to the
Guide for the Care and Use of Laboratory Animals with prior approval by
the InstitutionalAnimalCareandUseCommitteewithin theAAALACaccre-
dited program at the University of North Carolina at Chapel Hill (UNC-CH)
(Animal Welfare Assurance Number: A-3410-01).
De-identified human semen samples were obtained from excess stocks
collected by the UNC-CH Fertility Clinic, Department of Obstetrics and
Gynecology. All human samples were from healthy donors with normal
semen parameters and screened for HIV (human immunodeficiency virus),
RPR (rapid plasma reagin: syphilis) and hepatitis. Criteria for selection of
donor sperm included normal morphology using strict criteria (World
Health Organization, 2010) and a post-thaw count of .80 × 106 motile
sperm. Semen samples were diluted 1:1 with TEST-yolk buffer (Prins and
Weidel, 1986) following collection, divided into aliquots with ≥20 × 106
sperm, and stored in liquid nitrogen. After thawing, sperm were isolated
from seminal plasma and cryoprotectant by low speed centrifugation
(365g) for 10 min througha90%colloidal silica suspension (ISolate, Irvine Sci-
entific, Santa Ana, CA, USA) at a 1:1 volume ratio. The upper layer was dis-
carded and the remaining sperm pellet was resuspended into 2 ml HEPES
buffered Sperm Washing Medium (Irvine Scientific) and centrifuged for
5 min at 365g. The washing step was repeated twice and the final pellet
was resuspended in 1–2 ml of HTF mediumwithout human serum albumin.
Spermwere incubated at378Cunder 5%CO2 in air for 2 h inHTFmedium
containing 50 or 100 mM T0501_7749. Effects on motility were monitored
by computer-assisted sperm analysis (CASA) with the Hamilton Thorne
CEROS imaging system, version 12.3H IVOS software (Goodson et al.,
2011). Sperm tracks (1.5 s) were captured at a frame acquisition rate of
60 Hz.Aliquotswere removedat30 min intervals to compare spermmotility
in the presence of inhibitors with motility in the DMSO vehicle control.
Motility analyses were repeated in modified HTF medium, omitting bovine
serum albumin (BSA) or human serum albumin or replacing BSA with
0.4 mM methyl-b-cyclodextrin and 0.01% polyvinyl alcohol (Hasegawa
et al., 2012). For each condition, experiments were repeated at least three
times with sperm from different mice or human donors. Sperm viability
was monitored by the uptake of propidium iodide by cells with damaged
plasma membranes, as described previously (Goodson et al., 2012).
Lactate production and accumulation in the medium was measured in
mouse sperm to monitor inhibitor effects on sperm glycolysis. Sperm were
incubated for 2 h+T0501_7749 under the same conditions used for motil-
ity analyses in HTF medium with 0.4 mM methyl-b-cyclodextrin and 0.01%
polyvinyl alcohol, except that lactate and pyruvate were omitted from the
medium. Osmolality of the medium was adjusted to 315 mOsm/kg with
5 M NaCl using a Model 3300 micro-osmometer (Advanced Instruments,
Norwood, MA, USA). Duplicate aliquots were removed at time 0 and 2 h,
centrifuged to remove sperm and assayed to measure lactate accumulation
in the medium. The spectrophotometric assay monitors the conversion of
lactate to pyruvate by lactate dehydrogenase in the presence of NAD+
and hydrazine (Pesce et al., 1975; Danshina et al., 2001). In this assay the
concentration of lactate in the sample is proportional to the increase in ab-
sorbance at 340 nm as NAD+ is reduced to NADH.
Statistical analyses were performed using Prism (GraphPad Software, La
Jolla, CA, USA). Data are shown as mean+ SEM and statistical significance
(P, 0.05) was calculated using either two-tailed unpaired t-tests or
two-way analysis of variance followed by Tukey’s multiple-comparison test.
Results
Structural differences between sperm
and somatic isozymes
Bothmouse and human sperm require glycolysis (Miki et al., 2004; Nasci-
mento et al., 2008) and have GAPDHS isozymes with 83% amino acid
identity, suggesting that the mouse may be useful as a model system for
testing GAPDHS inhibitors as potential contraceptives. Alignment of the
amino acid sequences for human and mouse GAPDHS and GAPDH
shows that 68 amino acids are identical in the sperm isozymes (highlighted
in red in Fig. 1), but distinct from the corresponding amino acids in the
somatic isozymes. The proline-rich N-terminal regions of human (amino
acids 1–75) and mouse (amino acids 1–105) GAPDHS are not included
in the alignment since homologous regions do not exist in their somatic
counterparts. Unless noted otherwise, we will refer to amino acid num-
bering based on the sequences of human GAPDHS (top row in Fig. 1)
and humanGAPDH(bottom row in Fig. 1). Each subunit of the tetrameric
enzyme has an NAD+-binding domain in the N-terminal segment of the
protein preceding the active site C224 and a catalytic domain in the
C-terminal half. Eight amino acids in the C-terminal domain that have
crucial roles in catalysis (denoted by dots above the sequences in Fig. 1;
Seidler, 2013) are conserved in both sperm and somatic isozymes. Forty-
sixof the sperm-specific residuesare in theNAD+-bindingdomainand the
remaining 22 are in the catalytic domain.
We constructed homology models for mouse and human GAPDHS
and GAPDH based on the 2.0 A˚ crystal structure of Palinurus versicolor
GAPDH(PDB1CRW; Shen et al., 2000) to assess the three-dimensional
location of the sperm-specific amino acids. Models of the sperm iso-
zymes represent tGAPDHS without the proline-rich N-terminal exten-
sions. Most of the 68 sperm-specific amino acids noted in Fig. 1 are
located on the surface of the protein subunit (pink in Supplementary
Video S1). However, two regions with sperm-specific amino acids (red
in Supplementary Video S1) are closer to the active site. One region
near the center of the model is adjacent to the catalytic site where
both GAP (orange) and the nicotinamide ring of NAD+ (gray) bind.
The second region near the top of the model is at the opposite end of
the NAD+ binding site surrounding the adenine moiety of the cofactor.
To evaluate the potential for differential binding to the sperm and
somatic isozymes, we used SiteID in the SYBYL molecular modeling
program to identify three binding pockets surrounding the active site in
our tGAPDHS homology models (Fig. 2A). Subsequent comparisons
with high resolution crystal structures for human tGAPDHS (PDB 3H9E,
Chaikuad et al., 2011 and crystal structures solved in this study) and
human GAPDH (PDB 1U8F, Jenkins and Tanner, 2006) confirmed the
conformations of all three pockets. Pockets 1 and 2 (blue and green, re-
spectively, in Fig. 2A) contain the two regions with sperm-specific amino
acids noted in Supplementary Video S1. These amino acid differences
are highlighted in Fig. 2B, where structures of the sperm (pink) and
somatic (gray) isozymes are aligned and superimposed.
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Pocket 1 (blue in Fig. 2A) surrounds the substrate and the nicotina-
mide moiety of NAD+. It is formed by the side-chains of R85, I86,
L89, S193, S223, C224, H251, S252, Y253, T254, A255, P310, N388,
E389, Y392 and S393 of human GAPDHS (blue boxes in Fig. 1).
Pocket 1 includes two polar residues, S252 and Y253 (arrows in Fig. 1
and in the lower box of Fig. 2B), that are specific to the sperm isozymes
andare locatedwithin 6 A˚of the active sitewhere theyareflankedby two
of the amino acids required for catalysis (Fig. 1). Unlike the smaller,
hydrophobic residues (A180 and I181) present at corresponding posi-
tions in the somatic enzymes, S252 and Y253 have the potential for
hydrogen bond formation. Pocket 1 of human GAPDHS has a third
amino acid (P310) that is distinct from the corresponding residue in
human GAPDH (A238).
Pocket 2 (green in Fig. 2A) surrounds the adeninemoietyofNAD+ and
is formed by the side-chains of N81, G82, F83, G84, N105, D106, P107,
F108, C150, K151, E152, P153, E168, S169, T170, V172 and Y173 of
human GAPDHS (green boxes in Fig. 1). There are three sperm-specific
amino acids in pocket 2, C150, K151 and Y173 (arrows in Fig. 1 and in
the upper box of Fig. 2B) replacing E79, R80 and F102 in the somatic iso-
zymes. Both K151 and Y173 are within 2.5 A˚ of the adenine portion of
NAD+. C150 and K151 in GAPDHS are smaller than the corresponding
residues in GAPDH, and the C150 residue alters charge and provides a
Figure 1 Alignment of human (h) and mouse (m) glyceraldehyde 3-phosphate dehydrogenase, spermatogenic (GAPDHS) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) amino acid sequences. The human GAPDHS sequence (NP_055179) is shown on the top row, without the
proline-rich N-terminal region (amino acids 1–75) that is characteristic of the sperm isozyme. Similarly, mouse GAPDHS (NP_032111) in the second
row does not include the N-terminal 105 residues. Highlighted in red are amino acids that are conserved in these sperm isozymes, but distinct from the
corresponding amino acids in the somatic GAPDH isozymes shown in the third and fourth rows (mouse, AAH83149 and human, NP_002037). The
sperm isozymes have 83% amino acid identity, compared with the 70% identity between the sperm and somatic isozymes in each species. Dots
above the sequences denote amino acids required for catalysis. Colored boxes indicate amino acids that form pockets 1 (blue), 2 (green) and 3
(yellow) surrounding the active site, as identified by SiteID in the SYBYL molecular modeling program. Arrows denote sperm-specific amino acids in
pockets 1 and 2. Amino acids forming the S-loop are labeled.
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nucleophilic thiol group. The polar Y173 residue replaces a smaller, non-
polar residue inGAPDH(F102), shownpreviously to interact directlywith
NAD+ through hydrophobic contacts (Moras et al., 1975). It is interesting
to note that the five sperm-specific residues identified in pockets 1 and 2
are all highly conserved in mammalian GAPDHS orthologs identified in
Ensembl (Supplementary Table SI). C150 and Y173 in pocket 2 are also
conserved in reptile and fish orthologs.
Pocket3 (yellow in Fig. 2A) surrounds the inorganic phosphate binding
site and is formed by the side-chains of T256, Q257, K258, S264, A267,
R269, D270, G271, I279, P280, A281, S282, A304 and R306 of human
GAPDHS (yellow boxes in Fig. 1). This pocket does not contain sperm-
specific amino acids that are conserved between human and mouse
GAPDHS, although L195 in the somatic isozyme is replaced by A267
in human GAPDHS and D297 in mouse GAPDHS. Two additional resi-
dues (G300 and S311) are distinct only in mouse GAPDHS, replacing
D198 and A209 in the somatic isozyme.
To exploreGAPDHS structures in greater detail, we expressed recom-
binant humanandmouse tGAPDHSwithout their proline-richN-terminal
regions and compared multiple crystal structures for these sperm iso-
zymes. We solved three distinct crystal structures (Table I), including
the first apoenzyme crystal structures for human tGAPDHS (PDB 5C7L,
resolution 1.86 A˚) and mouse tGAPDHS (PDB 5C7I, 2.01 A˚). We also
obtaineda1.73 A˚holoenzymestructure forhumantGAPDHScomplexed
withNAD+ (PDB 5C7O). The coordinates and data files for these crystal
structures were deposited in the RCSB Protein Data Bank (http://www.
rcsb.org). Using subunit nomenclature previously established forGAPDH
(Buehner et al., 1974), the asymmetric unit of the human sperm NAD+-
bound holoenzyme is a dimer of O and P subunits, while the asymmetric
unit in the human and mouse apoenzyme structures is an O-Q dimer. In
both cases, the consensus tetramer of the GAPDH family is formed by
crystallographic symmetry that recapitulates the biological tetramer. As
reported for multiple GAPDH and GAPDHS structures (Cowan-Jacob
et al., 2003; Ismail and Park, 2005; Frayne et al., 2009), the active site
cysteines (C224 in human GAPDHS, C256 in mouse GAPDHS) in our
structures were oxidized to the sulfinic acid form, with clear electron
density for two oxygens attached to the cysteine sulfur.
The C2 space group of our NAD+-bound structure for human
tGAPDHS (PDB 5C7O) is the same as the published NAD+-bound
structures for this isozyme (PDB 3H9E and 3PWF, Chaikuad et al.,
2011), but distinct from theP3121 space groupof both apoenzyme struc-
tures. A novel feature of our NAD-bound tGAPDHS structure is the
presence of disulfide bonds between tetramers, linking the C150
residue of each monomer with the C150 of the symmetry-related
monomer in the adjacent tetramer. C150 is one of the highly conserved
sperm-specific amino acids in GAPDHS (pocket 2 in our homology
model), replacing E79 in the somatic isozyme. Figure 3A shows the tetra-
mers stacked and translated as they are in the holoenzyme crystal, with
the C150 residues shown as black spheres. Disulfide bonds between
these residues facilitate stacking of the tetramers parallel to the R-axis
of the C2 space group, which would continue along the direction of
this axis. The C150 residue is within 5 A˚ of the adenine ring in the
NAD+ bound within the crystal. As shown in the electron density plot
of this tetramer interface (Fig. 3B), thedisulfidebondbetweenC150 resi-
dues is the major conformation observed in this crystal structure
(occupancy ¼ 0.88). The minor non-disulfide-bonded conformation of
C150 has an occupancy of only 0.12.
Inter-subunit disulfide bonds are not found in either the human or
mouse tGAPDHS crystal structures without NAD+ (PDB 5C7L and
PDB 5C7I), where the loop containing C150 (residues 148–158) has a
slightly different conformation. Figure 3C shows two tetramers of the
human apoenzyme that are rotated and translated, illustrating that
they cannot stack as they do in the C2 holoenzyme (Fig. 3A). When
the human apo- and holoenzyme structures are superimposed (CCP4
Superpose, Krissinel and Henrick, 2004), the root-mean-square devi-
ation (RMSD) for all atoms of the C150 loop (including hydrogens and
side-chains) is 0.7 A˚, larger than the 0.38 RMSD over the entire struc-
ture. In the apoenzyme, the crystal packing changes since the relationship
Figure 2 Binding pockets and sperm-specific amino acids near the
active site. (A) To facilitate virtual screening, three binding pockets
were identified in our homology model of truncated GAPDHS
(tGAPDHS) using SiteID in the SYBYL molecular modeling program.
Surfaces are shown for pockets 1 (blue), 2 (green) and 3 (yellow)
which surround the glyceraldehyde 3-phosphate (GAP) substrate
(orange) and NAD+ cofactor (black). (B) Superimposed structures of
human tGAPDHS (pink, PDB 3H9E) and GAPDH (gray, PDB 1U8F)
highlighting the position of sperm-specific residues in pockets 1 (lower
box) and 2 (upper box).
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Figure 3 Features of the holo- (PDB 5C7O) and apoenzyme (PDB 5C7L) crystal structures of human tGAPDHS. (A) Two holoenzyme tetramers
stacked and translated as they are in the C2 crystal form. Subunits and axes are labeled as described by Buehner et al. (1974). The boundNAD+ cofactors
are shown in each subunit as black ball-and-stick structures. In this holoenzyme structure the sperm-specific C150 residues (highlighted as black spheres)
form disulfide bonds between tetramers, facilitating stacking parallel to the R-axis of the C2 space group. The S-loops of each subunit are shown as thicker
ribbons. (B) Electron density (2Fo-Fc contoured at 1s, where Fo is the observed structure factor and Fc is the calculated structure factor) around the inter-
tetramer disulfide bond seen in the NAD+-bound holoenzyme. The figure shows that there is a major disulfide-bonded conformation and a minor
non-disulfide-bonded conformation of C150. The distance between sulfur atoms (2.3 A˚) is slightly longer than the consensus disulfide bond, but there
is continuous electron density between them. (C) Apoenzyme tetramers are more open, packing in the P3121 crystal form without disulfides between
the C150 residues (black spheres).
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between monomers in the tetramer is slightly more open. For this
reason, the apposition of C150 residues and consequent disulfide
bonds that are facilitated in the holo space group are not allowed in
the trigonal space group that the apoenzyme forms.
Previous comparisons ofGAPDHcrystal structures indicate that differ-
encesbetween theapo-andholoenzymeoccurprimarily in theN-terminal
NAD+-binding domain (Skarzynski and Wonacott, 1988; Shen et al.,
2000; Yun et al., 2000), reflecting the conformational changes that occur
during cofactor binding. To assess conformational changes in the sperm
isozyme, we superimposed our human apo- and holo-tGAPDHS struc-
tures with CCP4 Superpose (Krissinel and Henrick, 2004) and plotted
theRMSDbetweenequivalentCabackbone atoms along thepolypeptide
chain for both subunits of the crystallographic unit (Fig. 4). Comparable to
the somatic isozyme, the greatest displacement for tGAPDHSwas seen in
the NAD+-binding domain (residues 76–223). Only minor variations
(,0.5 A˚) were apparent in most of the C-terminal catalytic domain.
However, there was a larger conformational difference between the
apo- and holo-tGAPDHS structures in the S-loop region (residues
253–276, thicker ribbon regions in Fig. 3, Banas et al., 1987), with
maximum displacement (0.88 A˚) centered at R265 and K266. Several
S-loop amino acids are included in binding pockets 1 and 3 identified
with SiteID, including the sperm-specific Y253 residue in pocket 1. Struc-
tural analyses of GAPDH indicate that the S-loops form the core of the
tetrameric enzyme, making contacts with neighboring subunits across
the R and P axes (Biesecker et al., 1977). Supplementary Video S2 illus-
trates the conformational change in the GAPDHS S-loop that occurs
when NAD+ binds.
We also compared the mouse and human tGAPDHS apoenzyme
structures (Fig. 5) by superimposing the Ca backbone atoms using
CCP4 Superpose (Krissinel and Henrick, 2004). The overall arrange-
ments of helices and strands in these structureswere in very good agree-
ment, with an average RMSDof 0.356 A˚ for all 1320main chain atoms in
theOsubunit and0.373 for theP subunits, not including side-chains since
there are sequence differences between the orthologs. Themost signifi-
cant relative displacement between the apoenzyme structureswas in the
surface loop formedby residuesW158-P164of human tGAPDHS (black
arrow in Fig. 5). Four of the seven amino acids in this loop are different in
the human (WRAVGSP) and mouse (WSSIGNP) isozymes. The RMSD
of the 28 main chain atoms for this loop is 1.08 A˚. The position of
this loop is unlikely to alter the novel structural features as described
for human tGAPDHS, including potential disulfide bonds and S-loop
conformational changes (which occur in the regions highlighted in red
in Fig. 5).
Virtual screening to identify compounds
predicted to inhibit GAPDHS selectively
With the goal of identifying selective inhibitors of GAPDHS, we used
the SYBYL FlexX algorithm to compare docking of compounds from
the Maybridge small molecule database into the binding pockets of the
sperm and somatic isozymes. The Maybridge collection used for this
screen included over 300 000 organic compounds designed to exhibit
diverse ring structures with drug-like characteristics. We first pre-
screened the Maybridge compounds on the basis of size to eliminate
compounds that did not fit into the three pockets identified by SiteID.
The remaining compounds (up to 8000) were docked with FlexX into
each of the pockets, comparing predicted binding in both mouse and
human tGAPDHS with the somatic isozyme in each species. Protein-
ligand interaction scores were determined for each isozyme, with
more negative scores reflecting tighter binding. Discrimination scores
were calculated as the difference between the interaction scores for
the sperm and somatic isozymes. For compounds with the largest dis-
crimination scores for the human isozymes, docking was repeated
Figure 4 Root-mean-square deviation (RMSD, A˚) between equiva-
lent Ca atoms along the polypeptide chains of the O and P subunits
when the human apo- and holo-tGAPDHS crystal structures (PDB
5C7L and PDB 5C7O) are superimposed. Displacement is greatest
within the N-terminal NAD+-binding domain and in the S-loop (resi-
dues 253–276) within the catalytic domain.
Figure 5 Mouse (green, PDB 5C7I) and human (blue, PDB 5C7L)
tGAPDHS apoenzyme structures superimposed along their Ca back-
bones. The largest displacement between the structures was seen in a
surface loop (black arrow) that is not close to the S-loops or the
C150 residues that form disulfides in the holoenzyme (highlighted in
red).
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thirty times to identify compounds that docked consistently within the
predicted binding pocket. Following cluster analysis and visual inspection
for drug-like properties and distinct scaffolds, we selected 25 represen-
tative compounds for further testing in enzyme assays. These com-
pounds had discrimination scores between 22.2 and 217.6 and were
predicted to form hydrogen bonds within one of the pockets of the
sperm isozyme (eleven pocket 1, eleven pocket 2 and three pocket
3 compounds).
Testing compounds to compare inhibition
of GAPDHS and GAPDH
Wetested predicted inhibitors in a spectrophotometric assayof enzyme
activity that measures NADH accumulation at 340 nm (Schmalhausen
et al., 1997), initially comparing inhibition of mouse tGAPDHS and
GAPDH. Two compounds inhibited 50% mouse tGAPDHS activity
at concentrations that did not alter activity of the somatic enzyme, but
complete inhibition was not achieved because these compounds exhib-
ited limited solubility at higher concentrations. To estimate IC50 values,
detailed dose–response assays were conducted comparing inhibition
of human tGAPDHS and GAPDH.
T0501_7749 (IUPACName: 2-[2-amino-3-(4-methylphenyl)sulfonyl
pyrrolo[3,2-b]quinoxalin-1-yl]-1-(4-nitrophenyl)ethanol; structure shown
in Fig. 6A) inhibited .60% human tGAPDHS activity at a concentration
of 5 mM(Fig. 6B). IC50 values, calculated using the four parameter nonlinear
model (Prism, Graphpad Software), were 1.2 mM for human tGAPDHS
and 38.5 mM for human GAPDH, indicating that T0501_7749 inhibited
the sperm isozyme with .10-fold selectivity. FlexX docking predicted
that T0501_7749 binds in pocket 1 of human tGAPDHS (Fig. 6C),
forming hydrogenbondswithY253 andP310, two residues that are distinct
from the somatic isozyme. T0501_7749 did not form bonds with the cor-
responding amino acids (I181 and A238) when docked in humanGAPDH,
interacting instead with pocket 1 residues (R13, T182, A183) that are
shared in the sperm and somatic isozymes (Fig. 6D).
T0506_9350 (IUPAC Name: 1-cyclohexyl-3-[4-[(4-methoxyphenyl)
sulfamoyl]-2-nitroanilino]urea; structure shown in Fig. 7A) inhibited
60% human tGAPDHS activity at a concentration of 200 mM
(Fig. 7B). Consistent inhibition was observed with this compound only
when the temperature of the 30 min pre-incubation period with
enzyme was reduced to 48C. Although T0506_9350 is not a very
potent inhibitor, it did exhibit partial selectivity for the sperm isozyme,
with estimated IC50 values of 95.8 mM for GAPDHS compared with
Figure6 Properties of T0501_7749. (A)Chemical structure of this small-molecule inhibitor. (B)Dose–response curvesmonitoring inhibition of human
tGAPDHS (red, n ¼ 3–6 for all concentrations except first and last, where n ¼ 2) andGAPDH (black, n ¼ 4–16) in the presence of 2 mMGAP and 2 mM
NAD+. (C) FlexXpredictedbinding poseofT0501_7749withinpocket1 (blue)of human tGAPDHS, forming hydrogenbonds (dotted lines)withY253and
P310, which are distinct from the corresponding residues (I181 and A238) in GAPDH. The sperm-specific residues (S252 and Y253) in pocket 1 are high-
lighted in red. (D) In the somatic isozyme, FlexX predicted that T0501_7749 forms hydrogen bonds with three pocket 1 residues that are shared with the
sperm isozyme (R13, T182, A183). GAPDH amino acids (A180, I181) corresponding to the sperm-specific residues are highlighted in gray.
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860 mMforGAPDH. FlexXdocking predicted thatT0506_9350binds in
pocket 2 of tGAPDHS forming five hydrogen bonds with two sperm-
specific residues, Y173 and K151 (Fig. 7C). The corresponding residues
in GAPDH (F102 and E79) were not predicted to bind to T0506_9350.
Instead, docking predicted hydrogen-bond interactions with GAPDH
residues (F11, D35 and T99) that are shared with the sperm isozyme
(Fig. 7D).
Kinetic analyseswere conducted to determine themodesof inhibition
and Ki values for T0501_7749 and T0506_9350, and the resulting
Lineweaver–Burk plots for human tGAPDHS are shown in Fig. 8. Each
double reciprocal line (1/Vo versus 1/[S]) shows the effects of a single
inhibitor concentration with variable concentrations of either GAP
(Fig. 8A and C) or NAD+ (Fig. 8B and D). When GAP concentrations
vary, lines representing higher concentrations of T0501_7749 have
steeper slopes (Km/Vmax) and smaller x intercepts (21/Km) with little
variation in the y intercept (1/Vmax) (Fig. 8A). This pattern of increasing
Kmandunchanging Vmax indicates thatT0501_7749 inhibition is competi-
tive with the GAP substrate. In contrast, the double reciprocal lines for
T0501_7749 are approximately parallel when NAD+ concentrations
vary (Fig. 8B), reflecting decreases in both Vmax and Km. This pattern
reflects uncompetitive inhibition, indicating that T0501_7749 binds fol-
lowing formation of the NAD+-tGAPDHS complex. Mean Ki values
for T0501_7749 were 10.9 mM for GAP and 7.1 mM for NAD+. Identi-
cal modes of inhibition were observed in kinetic analyses of mouse
tGAPDHS (Supplementary Fig. S1A and B), with mean Ki values of
19.9 mM for GAP and 31.6 mM for NAD+. Kinetic analyses indicate
that T0506_9350 inhibition of human andmouse tGAPDHS is competi-
tive with both GAP (Fig. 8C and Supplementary Fig. S1C) and NAD+
(Fig. 8D and Supplementary Fig. S1D). Mean Ki values were 63.3 mM
for GAP and 60.2 mM for NAD+ for human tGAPDHS, and 71.0 mM
for GAP and 56.9 mM for NAD+ for mouse tGAPDHS.
GAPDHS inhibitor effects on spermmotility
and metabolism
Based on the phenotype of GAPDHS knockout mice (Miki et al., 2004),
we expect inhibitors of GAPDHS to impair sperm motility by blocking
the glycolytic pathway. Our studies of inhibitor effects on sperm
Figure7 Properties ofT0506_9350. (A)Chemical structure of this small-molecule inhibitor. (B)Dose–response curvesmonitoring inhibition of human
tGAPDHS (red,n ¼ 4–6) andGAPDH(black,n ¼ 5–6) in thepresenceof 2 mMGAPand2 mMNAD+. (C) FlexXpredictedbindingposeofT0506_9350
within pocket 2 (green) of human tGAPDHS, forming hydrogen bonds (dotted lines) with Y173 and K151. These residues flank the adenine ring of NAD+
(see Fig. 2B) and are two of the three sperm-specific residues in pocket 2 (highlighted in red). (D) FlexX predicted that T0506_9350 binding to GAPDH is
removed from the corresponding amino acids (highlighted in gray), forming hydrogen bondswith pocket 2 residues that are sharedwith the sperm isozyme
(F11, D35, T99).
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focused on T0501_7749, since T0506_9350 had a very high IC50 and
limited stability above 48C. Using CASA, we first monitored effects on
mouse sperm motility in HTF medium containing 5 mg/ml BSA
throughout a 2 h incubation at 378C, conditions which support capacita-
tion (Goodson et al., 2011). Under these conditions, T0501_7749 did
not reduce the percentage of motile sperm. In other preliminary
Figure8 Lineweaver–Burk plots for the kinetic analysis of T0501_7749 (A andB) and T0506_9350 (C andD) inhibition of human tGAPDHS. Each line
(1/initial velocity Vo versus 1/substrate concentration [S]) shows the effects of a single inhibitor concentrationwith varying concentrations (0.05–2 mM)of
either GAP (A and C) or NAD+ (B and D). Inhibitors concentrations were: no inhibitor (B), 1 mM (V), 3 mM (O),10 mM (W), 20 mM (A), 30 mM (S),
80 mM (D), and 100 mM (x).
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studies, however, we found that T0501_7749 inhibition of GAPDHS en-
zymatic activity was substantially reduced by the addition of BSA or
sperm from GAPDHS knockout mice (not shown). Since these results
suggested that nonspecific protein binding to T0501_7749 reduced its
effectiveness, we assayed sperm motility in modified HTF medium.
T0501_7749 caused significant reductions in the percentage of motile
sperm during in vitro capacitation when BSA was replaced by 0.4 mM
methyl-b-cyclodextrin and 0.01% polyvinyl alcohol (Fig. 9A). More pro-
nounced reductions to ,15% motile sperm occurred within 30 min
when T0501_7749 incubations were conducted in HTF medium
without BSA or replacement compounds that facilitate capacitation
(Fig. 9B). After human samples were washed to remove seminal
plasma and cryoprotectant, T0501_7749 also significantly reduced the
percentage of motile sperm when incubated in HTF without human
serum albumin (Fig. 9C). Mean sperm viabilities at 120 min were com-
parable for control samples (48.0%) and samples treated with 100 mM
T0501_7749 (56.7%).
Sperm lactate production and accumulation in the medium during in
vitro incubations has long been used as an indicator of glycolytic activity
(Mann and Lutwak-Mann, 1981). T0501_7749 reduced lactate produc-
tion by ≥50% (P ¼ 0.017 for 100 mM T0501_7749 versus control)
when mouse sperm were incubated for 2 h in HTF containing 0.4 mM
methyl-b-cyclodextrin, 0.01% polyvinyl alcohol and glucose as the sole
substrate (Fig. 10), providing evidence that this compound inhibits
glycolysis in the target cell.
Discussion
Our structural analyses of GAPDHS focused on differences between the
sperm and somatic isozymes that are conserved between species, with
the goal of identifying regions uniquely important for GAPDHS function
that are suitable for selective targeting to achieve contraception. We
solved the first apoenzyme structures for human and mouse GAPDHS
and demonstrated very close alignment between these orthologs. Com-
parisonofourhumanapo- andholoenzymestructuresalso identified fea-
turesnot previously observed inGAPDHSorGAPDHcrystal structures.
Our virtual screen compared the predicted binding of compounds to the
sperm and somatic isozymes and identified two small-molecule inhibi-
tors with partial selectivity for the sperm isozyme. Furthermore,
T0501_7749, which inhibited GAPDHS with micromolar potency and
.10-fold selectivity, exhibited the expected inhibitory effects on
sperm motility and lactate production.
Figure 9 Inhibition of sperm motility by T0501_7749 monitored by computer-assisted sperm analysis. The percentages of motile sperm were deter-
mined at 30 min intervals, plotted as mean values+ SEM, with treatments compared by two-way analysis of variance followed by Tukey’s multiple-
comparison test. Mouse sperm were incubated in (A) human tubal fluid (HTF) medium with 0.4 mM methyl-b-cyclodextrin and 0.01% polyvinyl
alcohol replacing bovine serumalbumin (BSA)or (B)HTFwith neither these constituents norBSA. In bothmediaT0501_7749caused significant reductions
in the percentage of motile sperm compared with DMSO vehicle controls. For (A), n ¼ 3 and P ≤ 0.03 for 50 or 100 mM at 60, 90 and 120 min. For (B),
n ¼ 3 to 7; P ≤ 0.003 for 50 mMat30, 60 and 120 min; P, 0.0001 for 100 mMat these time points. (C) T0501_7749 also significantly reduced themotility
of human sperm incubated inHTFwithout human serumalbumin (n ¼ 8; P for 100 mMcomparedwith control, 0.05at60and 90 min,,0.01at120 min).
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In addition to its distinctive N-terminus, GAPDHS has 68 amino acids
that are conserved in the human and mouse sperm isozyme, but are dif-
ferent from the corresponding amino acid in the somatic isozymes of
both species. Although most of these sperm-specific residues are on
the surface, five are clustered in pockets 1 and 2 surrounding the
binding sites for GAP and NAD+. Chaikuad et al. (2011) noted that dif-
ferences in electrostatic properties in these two regions may contribute
tokinetic differencesbetween the spermand somatic enzymes, notably a
lower Km and increased catalytic efficiency for tGAPDHSwith respect to
NAD+. Two sperm-specific residues, S252 and Y253, are in pocket 1
surrounding the substrate and the nicotinamide portion of NAD+.
Y253 is predicted to bind to the T0501_7749 selective inhibitor. This
residue also provides a potential phosphorylation site that is not
present in the somatic isozyme. The sperm-specific K151 and Y173 resi-
dues are in binding pocket 2 where they are localized within 2.5 A˚ of the
adenine moiety of NAD+. In multiple GAPDH orthologs this region is
important for cofactor binding and induction of conformational
changes that precede catalysis (Skarzynski and Wonacott, 1988; Shen
et al., 2000; Yun et al., 2000). Another sperm-specific residue, C150,
is located in the same pocket between K151 and Y173, but is oriented
in the opposite direction away from NAD+ (Fig. 2).
Highly conserved in mammalian, reptile and fish orthologs of
GAPDHS, C150 is an interesting feature of the sperm isozyme since it
mediates disulfide bond formation between adjacent tetramers in our
holoenzyme crystal structure (PDB 5C7O). Inter-tetramer disulfide
bondswerenotobserved in thepreviously publishedhuman spermholo-
enzyme structure (PDB 3H9E, Chaikuad et al., 2011), with the same
space group and very similar unit cell constants. Perhaps differences in
protein production and crystallization conditions may have contributed
to a slightly more ‘oxidized’ tGAPDHS in this study, resulting in
packing that allows disulfides and the oxidation of the active site cysteine
to sulfinic acid. Recombinant tGAPDHS has enhanced stability com-
pared with the somatic isozyme, exhibiting greater resistance to inacti-
vation by heat or guanidine hydrochloride (Elkina et al., 2010; Kuravsky
et al., 2014). Furthermore, the native proteinwith itsN-terminal exten-
sion is tightly bound to the fibrous sheath in mature sperm (Westhoff
and Kamp, 1997; Bunch et al., 1998), persisting when this cytoskeletal
structure is isolated by sequential extraction with 1% Triton X-100,
0.6 M potassium thiocyanate and 6 M urea (Krisfalusi et al., 2006).
Disulfidebond formation betweenGAPDHS tetramersmay contribute
to the stability of this protein and the protein complexes that form
the fibrous sheath. Further studies are needed to assess disulfide
bond formation between the highly conserved C150 residues of
GAPDHS during flagellar formation and during maturation in the epi-
didymis, where disulfide linkages increase in both head and tail proteins
of mammalian sperm (Calvin and Bedford, 1971; Balhorn, 2007; Baker
et al., 2015).
Although we were unable to obtain crystals of tGAPDHS complexed
with T0501_7749, our crystal structures should prove useful in the
design and analysis of selective inhibitors. The monoclinic C2 space
group of tGAPDHS holoenzyme structures (PDB 5C7O and PDB
3H9E, Chaikuad et al., 2011) is distinct from our apoenzyme structures
(PDB 5C7L and 5C7I), which belong to the trigonal P3121 space group
and cannot form disulfide bonds between tetramers. Comparison of
our apo- and holoenzyme structures confirms that GAPDHS, like
GAPDH from multiple species (Skarzynski and Wonacott, 1988; Shen
et al., 2000; Yun et al., 2000), undergoes significant conformational
change in the N-terminal NAD+-binding domain when the cofactor
binds. Unlike GAPDH in these earlier structural comparisons,
GAPDHS also exhibits distinct conformational change in the S-loop
region (residues 253–276) of the catalytic domain upon cofactor
binding. The maximum displacement in this region occurs at basic resi-
dues R265 and K266. The basic residue at position 265 in GAPDHS (R
in human or K in mouse) replaces a nonpolar glycine in the somatic
isozyme. There are also sperm-specific amino acids (Y253 and H275)
at both ends of the S-loop. Previous studies suggest that the S-loops,
which extend across the R-axis (see Fig. 3) and interact with NAD+ in
the adjacent subunit, may contribute to cooperativity between subunits
for cofactor binding (Moras et al., 1975; Biesecker et al., 1977). A recent
study found that human GAPDHS exhibits positive cooperativity,
opposite to the negative cooperativity observed in mammalian
GAPDH (Kuravsky et al., 2015). Although this property was eliminated
by mutagenesis to disrupt the D311-H124 salt bridge (Kuravsky et al.,
2015), the role of S-loop amino acids in GAPDHS cooperativity has
not been explored to our knowledge.
S-loop residues also formone side of the selectivity cleft, which iswider
in trypanosomatid GAPDH structures and has been targeted for the
design of selective inhibitors to combat illnesses caused by these parasitic
protozoa (Verlinde et al., 1994; Suresh et al., 2001). This is an intersubunit
cleft across the R-axis that is adjacent to the adenosine ribose ofNAD+ in
the neighboring subunit. ‘Open’ (PDB 1ZNQ; Ismail and Park, 2005) and
‘closed’ (PDB 1U8F; Jenkins and Tanner, 2006) conformations of the
S-loophavebeen reported inhumanGAPDHstructures, although thedis-
tance between residues closest to NAD+ (S-loop P191 and F37 in the
Figure 10 Inhibition of mouse sperm lactate production by
T0501_7749.Mouse spermwere incubated for2 hunder the samecon-
ditions as in Fig. 9A, except that lactate and pyruvatewere omitted from
the HTF medium. Data are shown as mean values+ SEM for sperm
treatedwith 50 mM(n ¼ 1) or 100 mMT0501_7749 (n ¼ 3) compared
with control sperm incubatedwith equal amounts of the DMSO vehicle
(n ¼ 3). The reductionwas statistically significant when the 100 mMand
control treatments were compared using a two-tailed unpaired t-test
(*P ¼ 0.017).
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neighboring subunit) is similar in these two structures. These residues are
conserved in the sperm isozyme (P263andF108).Only the ‘closed’S-loop
conformation has been observed in both apoenzyme (human PDB 5C7L
and mouse 5C7I) and holoenzyme (human PDB 5C7O and PDB 3H9E,
Chaikuad et al., 2011) structures of GAPDHS. The S-loop P263 in our
holoenzyme structure (PDB 5C7O) is 3.8 A˚ from the 2′-hydroxyl of the
NAD+ in the neighboring subunit. Consequently, adenosine analogs
designed to fit in the larger trypanosomatid selectivity cleft are unlikely
to inhibit the sperm isozyme.
Two compounds predicted to bindmore tightly to GAPDHS than to
GAPDH in our virtual screen inhibited GAPDHS in enzymatic assays
and exhibited partial selectivity for the sperm isozyme. FlexX docking
predicted that both of these inhibitors interact with amino acids
that are conserved in human and mouse GAPDHS, but are distinct
from the corresponding amino acids in the somatic isozymes in
both species. Although both compounds exhibited limited solubility,
we found that T0501_7749 inhibited human GAPDHS with an esti-
mated IC50 of 1.2 mM and .10-fold selectivity. Kinetic analyses with
both human andmouseGAPDHS indicate that T0501_7749 competes
with GAP substrate binding following formation of the cofactor-
enzyme complex.
T0501_7749 appears to bind nonspecifically to BSA and other pro-
teins, hampering full evaluation of its effects on sperm function. Never-
theless, we demonstrated that this compound inhibited both glycolysis
and motility in mouse sperm when albumin in the medium was replaced
with methyl-b-cyclodextrin and polyvinyl alcohol. The percentage of
motile sperm was further reduced to ,15% when these additives and
BSAwereomitted completely.T0501_7749also caused significant inhib-
ition of human sperm motility, although the effect was not as pro-
nounced. It should be noted that the human sperm used in this study
were exposed to proteins from seminal fluid and egg yolk in the cryo-
preservation medium, potentially modulating the effectiveness of this
compound.
This study provides proof-of-principle evidence that GAPDHS can be
inhibitedwith at least partial selectivity and that small-molecule inhibitors
of this enzyme significantly reduce sperm glycolysis and motility.We are
currently using medicinal chemistry to optimize structure-activity rela-
tionships within the T0501_7749 scaffold, with the goal of improving
potency, selectivity and drug-like chemical properties. In addition, we
will continue to use structure-based cheminformatics approaches to
search for additional GAPDHS inhibitors, efforts that are informed by
our crystal structures.
Supplementary data
Supplementary data are available at http://molehr.oxfordjournals.org/.
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